June 13, 2022 Cognigenics, Inc. received an investment of $1.6 million from Fifth Set Ventures and Lionheart Ventures. This funding will support the company’s preclinical research program for developing next-generation mental health technology.
December 15, 2021 An early prototype of the company’s RNA therapy for anxiety and depression performed similarly to brand name pharmaceutical drugs in animal laboratory tests without any evidence of side effects.
September 1, 2021 In a second series of combined behavioral, neuroanatomical, and genomic studies in an animal model of anxiety and depression, the Cognigenics scientific team successfully demonstrated their platform technology delivers a uniquely-designed CRISPR cargo to cellular targets in the brain associated specifically with anxiety, depression, and emotional memory. The genomic modification of the specific cell targets occurs in animal treatments which were previously targeted in Cognigenics’ first experiment, which significantly ameliorated stress and anxiety. A third series of multimodal genetic neuroengineering experiments is underway to determine the time-dose interactive effects of the treatments using longer time courses and varying doses.
June 10, 2021 The company’s first behavioral experiment demonstrated statistically-significant anxiety reduction in mice receiving our gene therapy versus a control group.
April 15, 2021 Reagents manufactured for mice behavioral experiment.
March 24, 2021 Design completed for mice anxiety behavior experiment.
February 11, 2021 The company received additional angel funding.
January 6, 2021 Decision made to test wild-type mice anxiety reduction with intranasal CRISPR delivery.
November 27, 2020 Transgenic mice founder generation born.
October 16, 2020 Transgenic embryonic stem cells grown.
September 5, 2020 CRISPR reagents formulated for transgenic experiment..
August 21, 2020 Design competed for CRISPR-Cas9 reagents for research experiments.
July 15, 2020 The company received initial funding from early angel investors.

 

September 1, 2021
In a second series of combined behavioral, neuroanatomical, and genomic studies in an animal model of anxiety and depression, the Cognigenics scientific team successfully demonstrated their platform technology delivers a uniquely-designed CRISPR cargo to cellular targets in the brain associated specifically with anxiety, depression, and emotional memory. The genomic modification of the specific cell targets occurs in animal treatments which were previously targeted in Cognigenics’ first experiment, which significantly ameliorated stress and anxiety. A third series of multimodal genetic neuroengineering experiments is underway to determine the time-dose interactive effects of the treatments using longer time courses and varying doses.

June 10, 2021
The company’s first behavioral experiment demonstrated statistically-significant anxiety reduction in mice receiving our gene therapy versus a control group.

April 15, 2021
Reagents manufactured for mice behavioral experiment.

March 24, 2021
Design completed for mice anxiety behavior experiment.

February 11, 2021
The company received additional angel funding.

January 6, 2021
Decision made to test wild-type mice anxiety reduction with intranasal CRISPR delivery.

November 27, 2020
Transgenic mice founder generation born.

October 16, 2020
Transgenic embryonic stem cells grown.

September 5, 2020
CRISPR reagents formulated for transgenic experiment.

August 21, 2020
Design competed for CRISPR-Cas9 reagents for research experiments.

July 15, 2020
The company received initial funding from early angel investors.

June 26, 2019
Cognigenics, LLC incorporated by Dr. Dean Radin, John Mee and Dr. Barry Linder.